Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4213663 in Healthy Participants and Rheumatoid Arthritis
NCT07258849Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 33 weeks. Started Dec 2025; status: recruiting.
02
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07258849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258849.